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The precise molecular mechanisms that coordinate
apoptosis and autophagy in cancer remain to be
determined. Here, we provide evidence that the
tumor suppressor promyelocytic leukemia pro-
tein (PML) controls autophagosome formation at
mitochondria-associated membranes (MAMs) and,
thus, autophagy induction. Our in vitro and in vivo
results demonstrate how PML functions as a
repressor of autophagy. PML loss promotes tumor
development, providing a growth advantage to tu-
mor cells that use autophagy as a cell survival strat-
egy during stress conditions. These findings
demonstrate that autophagy inhibition could be
paired with a chemotherapeutic agent to develop
anticancer strategies for tumors that present PML
downregulation.INTRODUCTION
To become cancerous, cells must overcome the foolproof mech-
anism of cell death, thereby reducing their propensity to activate
self-destructive catabolic pathways in response to hostile envi-
ronmental clues (Hanahan and Weinberg, 2011). The induction
of apoptosis is the major route of cell death that is targeted byCell Re
This is an open access article under the CC BY-Nmany chemotherapeutic drugs, yet it is antagonized by multiple
cellular processes, including autophagy.
Autophagy plays dual roles in cancer; it can function as either a
tumor suppressor by preventing the accumulation of damaged
proteins and organelles or a survival pathway by suppressing
apoptosis and promoting the growth of established tumors
(Booth et al., 2014; Eisenberg-Lerner et al., 2009; Maiuri et al.,
2007; Marin˜o et al., 2014; Su et al., 2015).
Recent studies have indicated that autophagy represents an
important mechanism underlying chemotherapy resistance in
leukemia (Sehgal et al., 2015) and in solid cancers (Eisenberg-
Lerner et al., 2009; Sehgal et al., 2015), although the exact mo-
lecular mechanism underlying the effects of autophagy on
tumorigenesis must be further elucidated.
Here, we propose a role for promyelocytic leukemia protein
(PML) in the negative regulation of autophagy. PML is a tumor
suppressor that was initially identified because of its dysregula-
tion during the pathogenesis of acute promyelocytic leukemia
(APL) (Piazza et al., 2001). The fusion oncoprotein PML/RARa
can activate constitutive autophagy in APL cells, thereby
contributing to the anti-apoptotic function of PML/RARa. How-
ever, the precise mechanisms by which PML regulates auto-
phagy remain unknown.
Because PML dysregulation is associated with an extensive
range of malignancies, including solid tumors (Gurrieri et al.,
2004), we reasoned that completely understanding all of the mo-
lecular pathways that require PML for the control of cell death
and, consequently, of cancer progression is fundamental.ports 16, 2415–2427, August 30, 2016 ª 2016 The Author(s). 2415
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. PML Represses Autophagic Pro-
cesses
(A) Percentages of GFP-LC3 puncta-positive cells
in Pml WT and KO MEFs transfected with the
GFP-LC3 plasmid under basal conditions (fed)
and after starvation (starved). Bars, SEM. **p <
0.01, n = 4.
(B) Representative images of GFP-LC3 puncta in
MEFs. Scale bar, 10 mm.
(C) Conversion of endogenous LC3-I to LC3-II,
monitored via immunoblotting in Pml+/+ and
Pml/ MEFs cultured in regular medium (fed) or
without nutrients (starved).
(D) Ultrastructural evidence of higher autophagy
levels in MEFs in the absence of PML compared
with WT conditions basal conditions (fed) or after
serum deprivation (starved). Scale bar, 500 nm.
Bars, SEM. *p < 0.05, n = 3.
(E) Immunoblotting of endogenous LC3 in the liver
and skeletal muscle of fed or starved (24 hr) Pml+/+
and Pml/ mice.
(F) Immunoblot of subcellular fractions isolated
from Pml+/+ and Pml/ MEFs, where IP3R3
was used as an ER marker, Sigma 1-R as a
MAM marker, Cyt c as a mitochondria marker
and ATG14/STX17 as autophagosome formation
markers. C, cytosol; ER, endoplasmic reticulum;
MAMs, mitochondria-associated membranes;
Mp, pure mitochondria.RESULTS
PML Represses the Autophagic Process
To determine the possible involvement of Pml in the autophagic
process, we monitored autophagosome levels in wild-type
(Pml+/+) and Pml/ primary mouse embryonic fibroblasts
(MEFs) either under normal conditions (fed) or after serum
deprivation (starved). Autophagosomes were detected in live-
imaging experiments as fluorescent cytoplasmic dots that
concentrated microtubule-associated proteins 1 light chain
3A (MAP1LC3A, best known as LC3) fused to GFP. Such
GFP-LC3-positive dots were more frequent in Pml/ MEFs
than in wild-type (WT) MEFs under basal conditions (Figures
1A and 1B). The redistribution of LC3 to autophagosomes is
usually accompanied by its lipidation, causing an increase
in its electrophoretic mobility (and hence a shift from LC3-I
to LC3-II) (Klionsky et al., 2012). Accordingly, detection of
the conversion of LC3-I to LC3-II via immunoblotting con-
firmed that Pml/ MEFs contained higher levels of LC-3-II
than WT MEFs under basal conditions (Figure 1C). Following2416 Cell Reports 16, 2415–2427, August 30, 2016nutrient deprivation, autophagosome
formation was induced in WT MEFs at
levels similar to those found in Pml/
cells under fed conditions; conversely,
autophagosome formation did not signif-
icantly change after starvation and other
pro-autophagic stimuli in Pml/ MEFs
(Figures 1A–1C and S1A). Transmission
electron microscopy (TEM) confirmedthe increase in baseline autophagosomes in Pml/ MEFs
(Figure 1D).
Increased LC3-II abundance was also detected in the liver and
skeletal muscle of adult Pml/ mice (Figure 1E) compared with
WT animals. Interestingly, as observed above in vitro, LC3-II
could be induced via starvation (food deprivation for 24 hr) only
in WT mice (but not in Pml/ mice), in which LC3-II reached
the same level as that observed in Pml/mice under fed condi-
tions. Thus, we analyzed whether Pmlmight affect the formation
of autophagosomes. We found that two autophagosome
markers, ATG14 and STX17 (Hamasaki et al., 2013), were shifted
to the MAM compartments in Pml/ MEFs, suggesting
increased autophagosome biogenesis in the absence of Pml
(Figures 1F and S1B).
Control experiments revealed that short hairpin RNA (shRNA)-
mediated knockdown of Pml also increased the number of
GFP-LC3 puncta in WT MEFs, while reintroduction of PML
into Pml/ MEFs reduced GFP-LC3 puncta (Figures S1C and
S1D). Pharmacological blockade of autophagy using 3-methyla-
denine (3-MA), an inhibitor of the Beclin-1 (Becl1)-dependent
Figure 2. PML Localization at ER/MAM Do-
mains Controls the Levels of Autophagy
(A) Percentages of GFP-LC3 puncta-positive cells
induced by the transfection of erPML and nuPML
chimeras into Pml/ MEFs under resting condi-
tions (fed) and after serum deprivation (starved).
Bars, SEM. **p < 0.01, n = 4.
(B) Representative images of GFP-LC3 puncta
in Pml/ MEFs before and after re-introduction of
the two chimeras, erPML and nuPML. Scale
bar, 10 mm.
(C) Immunoblotting to detect LC3 in PML KO MEFs
after the re-introduction of erPML and nuPML chi-
meras both under basal conditions (fed) and after
serum deprivation (starved).
(D) Images of autophagic ultrastructures in Pml/
MEFs following the transfection of erPML and
nuPML chimeras. Scale bar, 500 nm. Bars, SEM.
***p < 0.005, n = 3.class III phosphoinositide 3-kinase (PI3K), blocked the exces-
sive formation of autophagosomes in Pml/ MEFs, indicated
by the similar amounts of LC3-GFP puncta contained in WT
and Pml/ MEFs (Figure S1E). Accordingly, knockdown of
Becl1 with two distinct shRNAs (Boya et al., 2005) reduced
the levels of LC3-II in Pml/ MEFs (Figure S1F). Conversely,
in vivo blockade of the last step of autophagy (which depends
on lysosomal proteases) by means of leupeptin (Esteban-
Martı´nez and Boya, 2015) failed to reduce the difference in
LC3-II formation observed between WT and Pml/ mouse
livers (Figure S1G). Similarly, bafilomycin A1 or NH4Cl, which
both abolish the acidification of lysosomes, caused an in-
creased abundance of LC3-II in both WT and Pml/ MEFs,
yet it did not abolish the difference in LC3-II formation between
MEFs with the two genotypes, suggesting that the absence of
Pml truly induces an increase in autophagic flux (Figures S1H
and S1I).Cell RePML Localization at Endoplasmic
Reticulum/MAM Contact Sites Is
Necessary for Modulating
Autophagy
The localizationofPMLatER/MAMcontact
sites (Figures S2A–S2C) is fundamental for
its pro-apoptotic activity via a calcium
(Ca2+)-mediated pathway (Giorgi et al.,
2010). Driven by this consideration, we
determined whether PML also plays a role
in thecontrol of autophagy in thesespecial-
ized domains. To address this question,we
took advantage of an erPML chimeric pro-
tein, which contains the entire PML protein
targeted to the outer surface of the ER (Fig-
ure S2D) and can rescue sensitivity to
apoptosis in Pml/ MEFs (Giorgi et al.,
2010). ErPML (but not a control construct
targeted to nuclei, nuPML) localized at
MAMs and suppressed the elevated levels
of autophagy when re-introduced intoPml/ MEFs (Figures 2A–2D) comparable to those measured in
WT MEFs (Figure 1). Pml/ MEFs re-transfected with erPML
(but not with nuPML) acquired the ability to increase autophagy
in response to starvation (Figures 2A–2C). Hence, the presence
of PML at MAMs may be important for the repression of auto-
phagy. Accordingly, nutrient deprivation-dependent autophagy
induction in WT cells was accompanied by the delocalization of
Pml from ER-mitochondria contact sites (Figure S2E).
p53 Drives PML Localization at MAMs
Previously, the role of p53 in the regulation of autophagy was
proposed to depend on its localization (Tasdemir et al., 2008).
Cytoplasmic p53, particularly when associated with the ER
membranes, represses basal pro-survival autophagy, whereas
nuclear p53 fails to do so (Tasdemir et al., 2008). However, the
precise molecular mechanism by which p53 suppresses auto-
phagy remains elusive.ports 16, 2415–2427, August 30, 2016 2417
Figure 3. Delocalization of PML from the MAMs Is p53 Dependent
(A) Immunoblot detection of PML in p53/ MEF fractions. C, cytosol; ER, endoplasmic reticulum; MAMs, mitochondria-associated membranes; Mp, pure
mitochondria.
(B) Pre-embedding immunogold labeling of PML in p53+/+ and p53/ MEFs. In WT cells, PML localizes mainly at discrete sites in the nucleus (PML nuclear
bodies) and on the ER, outer mitochondria membrane (OMM) and MAMs (arrows indicate PML-positive MAMs). In p53/MEFs, while PML still localizes at PML
nuclear bodies and on the ER membranes, the association with OMM and in particular the presence at MAMs is reduced (arrows indicate PML negative MAMs).
Scale bar, left panel, 1 mm; upper-right panel, 500 nm; lower-right panel, 250 nm.
(legend continued on next page)
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Because of the tight interaction between p53 and PML (Ablain
et al., 2014; Guo et al., 2000; Papa et al., 2012; Pearson and
Pelicci, 2001), we sought to investigate the possible effect of
PML on autophagy in relation to p53. Therefore, we evaluated
p53 and PML localization at points of close contact between
the ER and mitochondria in Pml/ and p53/ backgrounds,
respectively. Subcellular fractionation of MEFs with distinct
genotypes revealed that p53 protein was associated with
MAMs irrespective of the absence or presence of Pml (Fig-
ure S3A), suggesting that Pml does not control the subcellular
localization of p53. In stark contrast, in the absence of p53,
Pml delocalized from MAMs without an overall change in its
expression (Figures S3B and S3C), as shown by comparative
subcellular fractionation followed by immunoblots, immunogold
detection by electron microscopy (EM) and immunofluores-
cence (IF) analyses of WT and p53/ MEFs (Figures 3A–3C
and S3D). These results suggest that PML might function as a
master regulator of autophagy downstream of p53.
This concept was confirmed by the introduction of the erPML
chimera into p53/MEFs. Indeed, the forced localization of Pml
at MAMs in p53/ cells (Figure 3D) reduced autophagosome
formation (Figures 3E–3G). Similarly, the re-introduction of
p53wt, which also localizes at the ER and MAMs (Giorgi et al.,
2015b), engages PML at those contact sites (Figures 3H, 3I,
and S3E) and suppresses signs of enhanced autophagy in
p53/ cells (Figures S3F and S3G). Furthermore, a p53 mutant
(p53K382R) that is unable to inhibit autophagy when re-introduced
into p53/ cells (Morselli et al., 2011) (Figures S3F and S3G)
failed to localize at the ER/MAMs in p53/ cells and also failed
to rescue Pml localization to MAMs (Figures 3H, 3J, and S3H).
Intriguingly, we observed, by means of proximity ligation assay
(PLA), that PML interacts with p53wt in large extent in the nu-
cleus, but also in regions enriched of MAMs marker (Figure S3I).
Accordingly, this ability is lost in cells expressing the p53K382R as
this mutant is also reported to have reduced ability to bind PML
(Pearson et al., 2000). Overall, these results strongly suggest that
p53 maintains proper Pml localization at MAM domains that is
fundamental for the repression of autophagy.
Pml Controls Autophagy through the AMPK/mTOR/Ulk1
Pathway
Autophagy is activated as a pro-survival mechanism in response
to various cellular stresses associated with an insufficient energy
supply (Amaravadi et al., 2011; Galluzzi et al., 2014). The auto-
phagy-signaling network is controlled by a variety of kinases.(C and D) The co-localization of PML (red) and Sigma 1-R-EGFP (used as a M
introduction of the erPML chimera was analyzed based on immunofluorescence
two stains. The lower-right panels display the PML signal overlaid with MAMs
(MAMsPML: Manders coefficient for PML staining was calculated according to M
Sigma 1-R marker). Scale bar, 10 mm.
(E–G) Reduced levels of autophagy were observed in p53/ MEFs following erP
(E and F) and on immunoblotting to detect LC3-I conversion into LC3-II (G). Repr
(H) PML and p53 localization following the re-introduction of p53wt as analyzed via
marker, Sigma 1-R as a MAM marker, Tubulin as a cytosolic marker and Cyt
mitochondria-associated membranes; Mp, pure mitochondria.
(I and J) Immunofluorescence of Pml (red) and p53 (blue) in H1299 cells after the re
the merged image of the two stains. The lower-right panels display the Pml signa
LUT. Scale bar, 10 mm.In particular, a complex that includes AMP-activated protein
kinase (AMPK), mammalian target of rapamycin (mTOR), and
unc-51-like kinase 1 (Ulk1) has emerged as important for the
regulation of autophagy (Kim et al., 2011; Nazio et al., 2013).
Thus, we examined the relationship between PML-dependent
autophagy and this multiprotein complex.
AMPK is a conserved energy-sensing kinase that is activated
by phosphorylation in response to low cellular energy levels (Mi-
haylova and Shaw, 2011). Previously, we reported that, in the
absence of PML, cells produced less ATP after agonist stimula-
tion (Giorgi et al., 2010). As the ratio of AMP to ATP represents an
important means of regulating the activity of AMPK, we exam-
ined the role of AMPK by quantifying its phosphorylation. As
expected, Pml/MEFs exhibited increased levels of phosphor-
ylated AMPK (Figure 4A), which correlated with enhanced
autophagy, compared with that of WT MEFs. Accordingly, the
downstream AMPK substrate acetyl CoA carboxylase was
hyper-phosphorylated (Figure 4A). Higher levels of AMPK phos-
phorylation, correlating with increased autophagy, were also
observed in the liver and skeletal muscle of adult Pml/ mice
compared to WT (Figure 4B).
In contrast to AMPK, mTOR activity reflects a higher energy
status with the consequent inhibition of autophagy (Kim et al.,
2011). AMPK and mTOR have recently been proposed to regu-
late autophagy through the coordinated phosphorylation of
Ulk1 (Egan et al., 2011; Kim et al., 2011). To determine whether
AMPK activation in the absence of Pml promotes autophagy
by activating Ulk1, we examined the phosphorylation levels of
both Ulk1 and mTOR. In agreement with the findings of Kim
et al. (2011), increased levels of LC3 lipidation in either Pml/
cells or Pml KO mice tissues were associated with Ulk1 hyper-
phosphorylation (which reflects Ulk1 activation), together with
reduced phosphorylation of mTOR and its substrate p70S6K
(which reflects mTOR inhibition) (Figures 4A and 4B). These re-
sults are consistent with the possibility that PML controls auto-
phagy through the AMPK/mTOR/Ulk1 pathway.
The critical role of Ca2+ in the formation of autophagosomes
has recently been emphasized (Ca´rdenas et al., 2010). In addi-
tion to a high concentration of AMP, AMPK activity is upregu-
lated through the inhibition of mitochondrial Ca2+ uptake due
to reduced Ca2+ release via the inositol triphosphate receptor
(IP3R) (Ca´rdenas et al., 2010). Pml/ cells display a reduced
Ca2+ transfer from the ER to mitochondria via IP3R, which pro-
tects cells from apoptosis (Giorgi et al., 2010). To verify whether
downregulated ER-mitochondrial Ca2+ transfer is important forAM marker, green) in (C) p53/ MEFs and in (D) p53/ MEFs following re-
using confocal images. The lower-left panels display the merged image of the
(MAM boundaries are highlighted in yellow) in a rainbow lookup table (LUT)
anders coefficient method as the proportion of PML signal overlapping with the
ML transfection as determined based on the percentage of LC3-GFP puncta
esentative images are shown. Bars, SEM. **p < 0.01, n = 4. Scale bar, 10 mm.
immunoblotting in H1299 p53/ cell fractions, where IP3R3was used as an ER
c as a mitochondria marker. C, cytosol; ER, endoplasmic reticulum; MAMs,
-introduction of p53wt (I) and mutant p53K382R (J). The lower-left panels display
l overlaid with MAMs (MAM boundaries are highlighted in yellow) in a rainbow
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Figure 4. PML Modulates Autophagy
through the AMPK/mTOR/Ulk1 Pathway in
a Ca2+-Dependent Manner
(A) Immunoblot detection of the phosphorylation
status of AMPK, ACCa, p70S6K, mTOR, andUlk1 in
Pml+/+ and Pml/ MEFs.
(B) Detection of autophagy and AMPK-mTOR-
Ulk1 phosphorylation levels in the liver and skeletal
muscle of Pml+/+ and Pml/ mice.
(C) Representative traces of increased mitochon-
drial Ca2+ levels in Pml/ MEFs after MCU over-
expression. Pml/: [Ca2+]m peak 33.7 ± 2.55;
Pml/ + MCU: [Ca2+]m peak 59.2 ± 6.22) SEM.
**p < 0.01, n = 3.
(D–F) Quantification of autophagy in Pml/ MEFs
following MCU overexpression via (D and E) anal-
ysis of GFP-LC3 puncta or (F) immunoblotting.
Representative images are shown. Bars, SEM.
**p < 0.01, n = 3. Scale bar, 10 mm.
(G) Schematic model of autophagy regulation by
PML. In theabsenceofPml, the releaseofCa2+ from
the ER into the mitochondria and the production of
ATP are reduced. This low-energy status induces
AMPK activation, mTOR inhibition, and Ulk1 phos-
phorylation, leading to increased autophagy.the induction of autophagy in Pml/ cells, we increased mito-
chondrial Ca2+ uptake in Pml/ cells by overexpressing the
mitochondrial Ca2+ uniporter (MCU) (Baughman et al., 2011;
De Stefani et al., 2011). MCU overexpression in Pml/ MEFs
increased the ability of mitochondria to accumulate Ca2+ (Fig-
ure 4C) and was sufficient to repress autophagy (Figures 4D–
4F) by reducing the amount of activated AMPK (Figure 4F),
suggesting that PML controls autophagy at ER-mitochondria
contact sites by its effects on Ca2+ homeostasis (Figure 4G).
Loss of PML Enhances Resistance to Metabolic Stress
As a homeostatic process, autophagy plays a crucial role during
metabolic stress in an attempt to maintain/restore cellular ho-
meostasis (Degenhardt et al., 2006; Rabinowitz and White,
2010). Upon starvation, WT cells exhibited a rapid decrease in
ATP production, as demonstrated previously (Tasdemir et al.,
2008), whereas cells lacking PML maintained high ATP levels2420 Cell Reports 16, 2415–2427, August 30, 2016during stress (Figure 5A). Accordingly,
Pml/ cells maintained a higher mito-
chondrial membrane potential (Jm) under
stress conditions compared to WT con-
trols (Figure 5B). This autophagy-depen-
dent energized status of Pml KO cells
conferred enhanced resistance to cell
death (Figure 5C), favoring cell growth un-
der unfavorable conditions (Figure 5D),
such as those present in tumors.
We confirmed this energized status of
Pml KO cells by analyzing mitochondrial
function in response to metabolic stress.
The oxygen consumption rate (OCR)
was used as readout of mitochondrial
basal respiration and ATP-linked respira-tion in Pml+/+ and Pml/MEFs. As shown in Figure 5E, the loss
of PML under basal conditions induced only a minor reduction in
basal and ATP-dependent OCRs. Interestingly, whenMEFswere
deprived from glucose, WT cells displayed a dramatic reduction
in both basal and ATP-dependent OCRs, while theOCRwas only
slightly affected in Pml/ cells.
Accordingly, either genetic inhibition of autophagy (Becn1
shRNA) or re-introduction of the erPML chimera into Pml/
MEFs prevented the protection of such cells from death under
glucose-depleting conditions (Figures S4A–S4D). These results
indicate that enhanced autophagy is responsible for the resis-
tance of PML-deficient cells to nutrient stress.
Targeting Autophagy in PML-Null Cells Rescues
Chemotherapy-Induced Cell Death
Accumulatingevidencehas indicated thatmalignantcells inestab-
lished tumors utilize autophagy to resist chemotherapy-induced
Figure 5. PML Deletion Favors Cell Survival
under Stress Conditions Due to Autophagy
Activation
(A) Cytosolic ATP levels in Pml+/+ and Pml/
MEFs as measured by luciferase expression
under starvation conditions (glucose deprivation
for 15 min). **p < 0.01, compared to WT condi-
tions, n = 3.
(B) Analysis of mitochondrial membrane potential
(Jm) as measured by TMRM intensity in Pml
+/+
and Pml/ MEFs. Where indicated, cells were
deprived of glucose or exposed to 1 mM carbon-
ilcyanide p-triflouromethoxyphenylhydrazone
(FCCP). On the bottom-right side, representative
images of the TMRM signal in the presence or
absence of glucose are shown. Normalized
TMRM intensity is displayed as a rainbow LUT
(statistical analysis cross, average; line, median;
box, 25 and 75 percentile; bars, maximum and
minimum values; *p < 0.05, n = 3). Scale bar,
10 mm.
(C and D) Pml/ cells are more resistant to
metabolic stress-induced cell death than Pml+/+
cells as confirmed by (C) immunoblot for
apoptotic markers and by (D) cell viability assay.
Metabolic stress is induced by glucose depriva-
tion (3 hr for western blot and the indicated hours
for cell viability). Bars, SEM. *p < 0.05, ***p <
0.005, n = 3.
(E) Basal-dependent (i) and ATP synthase-
dependent (ii, + Oligomycin) mitochondrial O2
consumption rates (OCR) in Pml/ and Pml+/+
MEFs under starvation conditions (glucose, py-
ruvate, and glutamine deprivation for 1 hr). Bars,
SEM. **p < 0.01, ***p < 0.005, n = 4.cell death. Indeed, solid tumors in particular develop regions of
hypoxia and limited nutrient availability in their centers, creating
a microenvironment of metabolic stress. Under these hostile con-
ditions, autophagy activation promotes cell survival by providing
missing nutrients (Maes et al., 2013; Xu et al., 2013). Accordingly,
the inhibition of autophagy augments the response of tumor cells
to anticancer drugs (Chittaranjan et al., 2014; Sehgal et al., 2015;
Selvakumaran et al., 2013).
To confirm the role of PML in adaptation to metabolic stress,
we directly analyzed autophagy levels, mitochondrial respira-
tion, and PML localization in humanNB4 promyelocytic leukemia
cells expressing the PML-RARa oncogenic fusion protein,
which causes neoplastic transformation by disrupting the func-
tion of PML.
Treatment with arsenic trioxide (ATO), typically used in APL
therapy to degrade the PML-RARa (Lallemand-Breitenbach
et al., 2001), modulated autophagic machinery in NB4 cells (Fig-Cell Repures 6A–6C). Interestingly, we found that
short-term treatment of ATO, promoting
the selective proteasome-dependent
degradation of PML-RARa fusion protein
but not of PML, led to an increase in both
p62 and LC3-II levels, indicating a block
in the autophagic process (Figure 6C).Accordingly, treatment with an inhibitor of autophagic flux,
reported in Figure 6D, suggested that ATO interferes with auto-
phagosome clearance (Ren et al., 2011) and thus reverts the
APL condition through reduced autophagy efficacy.
Moreover, NB4 cells displayed a higher resistance to meta-
bolic stress (by means of measurements of oxygen consumption
during substrate deprivation) that reverted after ATO treatment
(Figure 6E), which also restored proper PML localization at
ER/MAM contact sites already in the leukemia background
(Figure 6F).
To further analyze the role of PML in cancer development, we
compared the sensitivity of Pml+/+ and Pml/ MEFs to the
chemotherapeutic agent 5-fluorouracil (5-FU) (Li et al., 2010).
As expected, Pml/ cells were protected from apoptosis (Giorgi
et al., 2010) compared to WT cells (Figures 7A and 7B). Pharma-
cological inhibition of autophagy by either 3-methyladenine
(3-MA) or the antimalarial drug chloroquine (CQ) (Figure S5A)orts 16, 2415–2427, August 30, 2016 2421
Figure 6. Selective Degradation of the PML-
RARa Oncogenic Fusion Protein in APL
Human Cancer Restores a Correct PML
Localization and the Sensitivity toMetabolic
Stress
(A) Quantification of LC3 dots in NB4 cells trans-
fected with the GFP-LC3 plasmid under basal
conditions (0 hr) and after ATO (1 mM) treatment.
Bars, SEM. **p < 0.01, n = 4.
(B) Representative images of GFP-LC3 dots
showing the effects of ATO on autophagic process
in NB4 cells.
(C) PML-RARa degradation and LC3-II and p62
accumulation after ATO treatment (1 mM) in NB4
cells. PML-RARa was detected monitoring the
band at 110 kDa either with a PML antibody or with
a RARa antibody.
(D) Analysis of autophagic flux in NB4 cells after
ATO treatment (1 mM).
(E) Quantification of basal (i) and Oligomycin ATP
synthase-dependent (ii) mitochondrial O2 con-
sumption rates (OCR) either in vehicle or ATO
treated NB4 cells under starvation conditions
(glucose, pyruvate, and glutamine deprivation for
1 hr). Bars, SEM. *p < 0.05, n = 7.
(F) Immunoblot of subcellular fractions isolated
from NB4 cells and PML protein quantification at
MAM regions and ER normalized to the amount of
Sigma 1-R and IP3R3. Where indicated, cells were
exposed to ATO treatment (1 mM, 12 hr). IP3R3,
Sigma 1-R and Cyt c was used as ER, MAMs, and
mitochondria marker, respectively.alone did not alter cell viability, yet it markedly increased
apoptosis when combined with 5-FU, and this effect was partic-
ularly remarkable for Pml/ MEFs (Figures 7A and 7B).
Next, we explored whether the synergistic effect of CQ and
5-FU was also applicable in vivo. Transformed Pml+/+ and
Pml/ MEFs that displayed levels of autophagy comparable
to those of primary cells (Figure S5B) were injected subcutane-
ously either into immunodeficient nu/nu mice or in syngeneic
mice, and the resultant tumor volumes were monitored. Pml/
cells exhibited a particularly high tumorigenic potential both
in vitro (Figures S5C–S5E) and in vivo (Figures 7C and S5F),
developing tumors that were 10-fold larger than those generated
fromWT cells (Figures 7C, 7D, and S5G) and with elevated signs
of autophagy (Figures 7E and S5H).
Compared with the control conditions (PBS), 5-FU treat-
ment slightly suppressed tumor growth, whereas 5-FU com-
bined with CQ greatly reduced the sizes of Pml/ tumors2422 Cell Reports 16, 2415–2427, August 30, 2016(Figures 7C and 7D). Treatment with
CQ alone had no significant effects
on tumor growth (Figures S5I and S5J).
Genetic inhibition of autophagy (by
means of Becn1 shRNA) in Pml/ cells
reduced their tumorigenic potential
either in vitro (Figures S6A and S6B) or
in vivo (Figures S6C and S6D) and
restored their sensitivity to chemo-
therapy (Figure S6E).Intravenous injection of a fluorescent probe (SR-FLIVO) was
used to detect apoptosis-associated caspase activation within
the tumors (Giorgi et al., 2015a). Pml/ tumors were completely
insensitive to 5-FU-induced apoptosis (Figure 7F), correlating
with higher levels of autophagy (Figure 7E), yet they responded
to the combined treatment with 5-FU and CQ by vigorous
apoptosis induction (Figure 7F) and immunoblot-detectable
caspase-3 maturation (Figure 7G). Knockdown of Beclin-1 in
Pml/ cells led to the generation of tumors that contained areas
undergoing apoptosis (Figures S6F and S6G) and that were less
abundant in Pml/ tumors transfected with a scrambled control
shRNA. Hence, elevated autophagy may be responsible for the
growth advantage of Pml/ cancers. Indeed, in human colonic
adenocarcinoma sampleswith reduced PMLprotein expression,
levels of LC3 detectable by immunohistochemistry were rela-
tively higher compared to those found in cancer tissues with
PML protein abundance (Figure 7H).
Figure 7. Inhibition of Autophagy Augments
the Cytotoxicity of Chemotherapy Treat-
ment in Pml KO Tumors
(A and B) Pml+/+ MEFs are sensitive to 5-fluoracil-
induced cell death (5-FU, 25 mM for 16 hr), whereas
Pml/ cells are resistant. Inhibition of autophagy
by treatment with 3-MA (2.5 mM for 16 hr) or CQ
(5 mM for 16 hr) increases apoptosis induced via
chemotherapy treatment with 5-FU (25 mM for
16 hr) in Pml/ MEFs.
(C) Tumor growth of Pml/ and Pml+/+ trans-
formed MEF xenografts.
(D) Representative images of mouse fibrosarcoma
xenografts.
(E) Increased levels of autophagy in tumors derived
from Pml/-transformed MEFs as analyzed by
immunoblotting. Tumors were excised on day 19
after inoculation.
(F) Analysis of apoptosis based on the intensity of
fluorescence (SR-FLIVO) emitted in tumor tissue
sections, accompanied by statistical analysis
(cross, average; line, median; box, 25 and 75
percentile; bars, maximum and minimum values;
***p < 0.005, n = 3). Scale bar, 50 mm.
(G) Increased cytotoxicity-chemotherapy effects
on Pml/ tumors after autophagy inhibition.
(H) Representative histological sections of human
colon cancer immunostained for PML and LC3
accompanied by statistical analysis expressed as
the percentage of staining intensity. Bars, SEM.
*p < 0.05, ***p < 0.005, n = 13. Magnification 203.DISCUSSION
Loss of PML Confers a Metabolic Advantage to Cells
under Nutrient Deprivation
Autophagy is an important homeostatic mechanism with a para-
doxical dual role: it can function as a cell survival pathway, sup-
pressing apoptosis, or it can lead to death. As a result, the
connection between autophagy and apoptosis is complex and
affects the treatment of diseases associated with cell death.
Alteration of the autophagic machinery is associated with
various human disorders, establishing autophagy as a therapeu-
tic target (i.e., a target for drug development). The connection of
autophagy with the development of cancer has been well estab-
lished, although the exact roles played by this process during
various stages of tumor progression are not yet clear and, in
some cases, are contradictory.Cell RepHere, we provide molecular insight
into the acquisition of tumor-promoting
behavior due to the loss of the PML pro-
tein. Pml is a tumor suppressor gene
that was originally related to the patho-
genesis of acute promyelocytic leukemia
(APL). However, the loss of PML was later
found to be a critical event in various hu-
man cancers (Gurrieri et al., 2004). We
recently identified an extra-nuclear tran-
scription-independent function of PML in
regulating cell survival through changesin Ca2+ signaling at ER/mitochondria contact sites (Giorgi
et al., 2010). Accumulating evidence has suggested that ER
and MAM domains play a prominent role in autophagy (Hama-
saki et al., 2013; Heath-Engel et al., 2008) and emphasized the
important role of IP3R and Ca2+ in autophagosome formation
(Ca´rdenas et al., 2010; Criollo et al., 2007); therefore, we sought
to investigate the role of PML in these processes.
We clearly demonstrated that the localization of PML at the
ER-mitochondria contact sites is fundamental not only for
apoptosis control, but also for autophagy regulation. At these
sites, PML represses autophagosome formation and, thus, auto-
phagy induction. We found that the mislocalization of PML away
from MAMs is necessary to activate autophagy in response to
stress and that the same mechanism occurs in the absence of
p53. Our data demonstrate that p53, which also localizes at
ER/MAMs (Giorgi et al., 2015b), operates as a bridge to maintainorts 16, 2415–2427, August 30, 2016 2423
the correct localization of PML. p53K382R mutants, which display
reduced interactions with PML (Pearson et al., 2000) and are un-
able to localize at MAMs, cannot preserve PML localization,
making them incapable of suppressing autophagy.
PML loss reduced IP3R-mediated Ca2+ transfer from the ER to
mitochondria. Mitochondrial Ca2+ stimulates tricarboxylic acid
(TCA) cycle dehydrogenases and subsequent mitochondrial
respiration and ATP production. A reduction in [Ca2+]m inhibits
this mechanism that activates AMPK (Cheng et al., 2013).
AMPK activates pro-survival autophagy (Ca´rdenas et al., 2010)
by a mechanism involving mTOR (Tasdemir et al., 2008) and
Ulk-1 pathways (Kim et al., 2011; Nazio et al., 2013). In our sce-
nario, PML-deprived cells use enhanced baseline levels of
autophagy to obtain an advantage during metabolic stress con-
ditions. Indeed, restoration of the Ca2+ signal in the context of a
Pml/ or p53/ background (by overexpression of MCU) re-
stores basal levels of autophagy. Cells lacking PML due to the
inhibition of Ca2+ release activity have slightly diminished bioen-
ergetics in terms of mitochondrial respiration and ATP produc-
tion that are sensed by AMPK, which activates autophagy.
Because oxygen and glucose supplies are often low in the tumor
microenvironment, autophagy, as catabolic process, is neces-
sary to obtain alternative carbons source to preserve normal
cellular bioenergetics (Ca´rdenas et al., 2010) and to confer resis-
tance to cell death to Pml KO cells. Lipid or glutamine catabolism
is considered the major alternative pathway to provide carbons
for mitochondria (Boroughs and DeBerardinis, 2015). PML pro-
motes lipid utilization by fatty acid oxidation (Carracedo et al.,
2013; Ito et al., 2012), excluding this pathway as a possible stim-
ulated carbon source when PML is lost. Furthermore, autophagy
can sustain mitochondrial respiration in a glutaminemetabolism-
dependent manner (Lin et al., 2012; Strohecker et al., 2013).
Thus, we could speculate that in the absence of PML, stimulated
glutamine catabolism by autophagy is used as an alternative
pathway to sustain mitochondrial activity and, thus, cell survival
during stress conditions.
These data, together with data presented in our previous pub-
lication, indicate that PML from MAMs acts on the transfer of
Ca2+ from the ER to the mitochondria, thus regulating both
apoptosis and autophagy. While the effect on apoptosis is
manifested in response to Ca2+-dependent apoptotic stimuli,
the stimulation of autophagy is a direct consequence of
reduced mitochondrial respiration. Thus, the loss of PML from
MAMs confers contemporary resistance to apoptotic stimuli
and metabolic stress, promoting cell survival in the tumor
environment.
Recent studies have suggested that autophagy represents an
important mechanism of resistance to cancer treatments. There-
fore, we further investigated the cross-talk between autophagy
and PML-related cell death using in vivo models. The prototypi-
cal PML-RARa-related promyelocytic leukemia model, NB4,
displays low levels of WT PML at MAMs. Exposure to ATO in-
duces degradation of PML-RARa and increased PML levels
at MAMs. As a result, ATO-treated cells display blocked auto-
phagy and reduced resistance to metabolic stress. Furthermore,
we observed that the absence of PML promotes tumor develop-
ment associated with resistance to anticancer drugs due to
increased autophagy levels in the tumor. Treatment with the2424 Cell Reports 16, 2415–2427, August 30, 2016autophagy inhibitors 3-MA and CQ restored chemotherapy-
related apoptosis. Therefore, our findings hold therapeutic impli-
cations for the treatment of solid tumors associated with PML
downregulation.
EXPERIMENTAL PROCEDURES
Cell Culture and Transfection
Primary Pml+/+ and Pml/ mouse embryonic fibroblasts (MEFs) and H1299
cells were cultured in DMEM supplemented with 10% fetal bovine serum
(FBS) (Life Technologies), 1% penicillin-streptomycin-glutamine (1003) liquid
(EuroClone).
Human APL NB4 cells were cultured in RPMI 1640 medium (Gibco) supple-
mented with 10% FBS (Gibco) and 1% penicillin-streptomycin (1003) liquid
(Gibco).
MEFs were transformed with SV40 large T antigen. MEFs were transfected
with the following plasmids: PML, erPML, nuPML (Giorgi et al., 2010), p53WT,
p53K382R (Morselli et al., 2011), MCU (De Stefani et al., 2011), andGFP-LC3 us-
ing a MicroPorator (Digital Bio). For PML depletion in WT MEFs, a specific
shRNA silencing lentiviral vector (Sigma) was used. H1299 cells were trans-
fected using a standard calcium phosphate procedure with p53WT and
p53K382R constructs, while NB4 cells were transfected with a GFP-LC3
plasmid by electroporation.
Procedures involving animals and their care were in conformity with institu-
tional guidelines, and all experimental protocols were approved by the animal
ethics committee. Pml+/+ and Pml/mice were bred and maintained accord-
ing to both the Federation for Laboratory Animal Science Associations and the
Animal Experimental Ethics Committee guidelines.
Autophagy Induction and Inhibition
The autophagic process was triggered in vitro as follows: serum deprivation
(EBSS, 1 hr), glucose deprivation (1 hr), rapamycin (100 nM, 24 hr in DMEM
with 10% FBS), and lithium treatment (10 mM, 24 hr in DMEM with 10%
FBS). Pharmacological inhibition of autophagy was performed by treating cells
with 2.5 mM 3-MA (16 hr) or 5 mMCQ (16 hr) in DMEMwith 10% FBS (Klionsky
et al., 2016; Mizushima et al., 2010). Genetically inhibition of autophagy was
performed by using shRNA targeting Beclin1 (psirna42-mbeclin) (Invitrogen).
ATO (arsenic trioxide, 1 mM) has been used on NB4 cells for 1 or 12 hr in
RPMI with 10% FBS). For in vivo studies on the effects of starvation, mice
were deprived of food for 24 hr.
Analysis of Autophagic Flux
Primary Pml+/+ and Pml/MEFs were treated either with the autophagy inhib-
itor NH4Cl (20 mM) or bafilomycin A1 (BafA1, Sigma) (100 nM) in DMEM with
10%FBS (Klionsky et al., 2012; Mizushima et al., 2010). NB4 cells were treated
with the autophagy inhibitor NH4Cl (20mM) in DMEMwith 10%FBS. For in vivo
determination of autophagic flux, lysosomal activity was blocked by leupeptin
(Boya et al., 2005).
TEM
Primary Pml+/+ and Pml/ MEFs and Pml/ MEFs expressing nuPML and
erPML were cultured in DMEM with 10% FBS and allowed to grow to 70%
confluence. Where indicated, the cells were subjected to serum starvation
conditions (EBSS, 30 min). After the cells received the indicated treatments,
they were fixed in formaldehyde and glutaraldehyde. Fixed samples were
post-fixed with osmium tetroxide, dehydrated, and embedded in Araldite Dur-
cupan ACM (Fluka).
Pre-embedding Immunogold Electron Microscopy
Cells were fixed with 4% formaldehyde in 0.1 M phosphate buffer (pH 7.4) for
1 hr at room temperature. Subsequently, cells were permeabilized, blocked,
and incubated sequentially with PML primary antibodies (Millipore MAB3738
or Abcam ab72137) and nanogold-conjugated secondary antibodies (Nanop-
robes) diluted in blocking buffer. After washes, cells were re-fixed in 1%glutar-
aldehyde, and nanogold was enlarged with gold enhancement solution
(Nanoprobes). Cells were post-fixed with osmium tetroxide, embedded in
epon, and processed into ultrathin slices. After contrasting with uranyl acetate
and lead citrate, sections were analyzed with a Zeiss LEO 512 electron
microscope.
Aequorin Measurements
All aequorin measurements were performed transfecting cells with the appro-
priate aequorin chimera targeted to the mitochondria (mtAEQmut), as previ-
ously described (Bonora et al., 2013).
Luciferase Measurements
Primary Pml+/+ and Pml/MEFs were transfected with cytosolic (untargeted)
firefly luciferase, and luminescence was measured as described (Jouaville
et al., 1999).
Subcellular Fractionation
Fractionations were performed as described previously (Vance, 1990; Wieck-
owski et al., 2009). IP3R3, Sigma 1-R, tubulin, and cytochrome c (Cyt c) were
used as markers for the ER, MAMs, cytosol, and pure mitochondria,
respectively.
Immunofluorescence Assay
Cells were fixed in 3.7% formaldehyde, washed, permeabilized with 0.1%
Triton X-100, and incubated overnight at 37C in a wet chamber with indicated
antibodies. Images were acquired using an LSM 510 laser scanning confocal
microscope (Zeiss).
Immunohistochemistry
Four-micrometer-thick sections were cut from formalin-fixed paraffin-
embedded blocks. One section for each block was routinely stained with
H&E for histological examination. Immunodetection of PML and LC3B was
performed using the Multimeric Detection Kit (Universal DAB Detection Kit
Ultraview, Roche Tissue Diagnostics) on a BenchMark XT automated immu-
nostainer (Gurrieri et al., 2004; Rosenfeldt et al., 2012).
Measurements of Mitochondrial Membrane Potential
Mitochondrial membrane potential (Jm) was assessed by loading cells with
10 nM tetramethyl rhodamine methyl ester (TMRM; Life Technologies,
T-668) for 35 min at 37C in Krebs-ringer bicarbonate (KRB) supplemented
with 1 mM CaCl2. Images were acquired using an inverted confocal
microscope.
XF Bioenergetic Analysis
OCRs in Pml+/+ and Pml/MEFs and NB4 cells were measured using a Sea-
horse XF96 instrument (Seahorse Biosciences) according to the manufac-
turer’s protocols.
Cell Proliferation and Viability Assay
Cells seeded in 6-well plates in triplicate and allowed to grow to 80% conflu-
ence were exposed to glucose deprivation for different time points (0, 1, 3, and
5 hr). Next, cells were centrifuged, washed with PBS, and counted using a Tali
image-based cytometer (Life Technologies).
Cell Survival Assay
Cells seeded in 12-well plates in triplicate and allowed to grow to 80% conflu-
ence were treated with vehicle (positive control), 25 mM 5-FU, 5 mM CQ or
25 mM 5-FU, and 5 mM CQ. After 48 hr, the cells were washed with PBS, fixed
in 4% paraformaldehyde, and stained with 0.1% crystal violet. Crystal violet
was dissolved with 1 mol/l acetic acid, and absorbance at 595 nm was
measured.
Wound-Healing Assay
Pml+/+ and Pml/ MEFs seeded in 6-well plates and grown to 90% conflu-
ence were treated with vehicle (positive control), 25 mM 5-FU, 5 mM CQ or
25 mM 5-FU, and 5 mM CQ 1 hr before wounding. The cell monolayer was
wounded with a P200 pipette tip. Cells were monitored and captured by
phase-contrast microscopy.Migration Assay
In vitro cell migration assays were performed using Costar Transwell perme-
able polycarbonate supports (8.0-mm pores) in 24-well plates (Corning).
Before seeding, the lower compartment was incubated with DMEM plus
10% FBS supplemented with vehicle (positive control), 25 mM 5-FU, 5 mM
CQ or 25 mM 5-FU, and 5 mM CQ. Non-migrated cells were removed using a
cotton swab, and migrated cells were fixed and stained with crystal violet.
Mouse Treatment Studies
Tumor xenografts or syngeneic tumors were obtained by subcutaneously im-
planting 5 3 106 transformed Pml+/+ and Pml/ MEFs in 50% Matrigel (BD
Biosciences) in female nude mice or sv129 mice, respectively. Tumor growth
was monitored daily, and tumor volumes were measured every other day.
Detection of Cell Death In Vivo
After an intravenous (i.v.) injection of 100 ml SR-FLIVO (Immunochemistry
Technologies) via the lateral tail vein, the FLIVO reagent was allowed to circu-
late in the mouse for 30 min before sacrifice. The tumors were excised, frozen,
sectioned, and stained for nuclei using DRAQ5 according to the manufac-
turer’s protocol (Cell Signaling Technology). Images were acquired using an in-
verted confocal microscope.
Statistical Analysis
Unless otherwise indicated, all assays were performed independently and in
triplicate, yielding comparable results. The data, which are presented as the
means ± SEM, were analyzed using Microsoft Excel (Microsoft), and signifi-
cance was determined by Student’s t tests. ***p < 0.005, **p < 0.01, and
*p < 0.05 were considered significant.
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